Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT03780647 Terminated - Clinical trials for Thoracic Outlet Syndrome

Assessment of the Impact of Thoracic Outlet Syndromes on the Performance at Work

PROCTB
Start date: December 17, 2018
Phase:
Study type: Observational

Thoracic outlet syndrome may associate neurologic, arterial and venous symptoms. The responsibility of repetitive movements and postural factors has been mentioned for long. Some tasks are hard to perform, and it seemed interesting to assess the consequences of this syndrome on the work capacity by a questionnaire, at the moment of diagnosis by Echo-Doppler

NCT ID: NCT03778528 Terminated - Cataract Clinical Trials

Evaluation of Ocular Lens Proteins in Cataract From Individuals With Down Syndrome

Start date: May 30, 2018
Phase:
Study type: Observational

This study involves the collection ocular lens tissue from individuals with Down syndrome and age-matched controls at the time of cataract surgery.

NCT ID: NCT03773081 Terminated - Clinical trials for Acute Coronary Syndrome

SOLVE-ACS: Bioresorbable Magnesium-Stents Magmaris in ACS Lesions

SOLVE-ACS
Start date: August 21, 2018
Phase: N/A
Study type: Interventional

The aim of the registry is to investigate the clinical performance of the Magmaris Magnesium Stent in STE-ACS and NSTE-ACS patients.

NCT ID: NCT03764761 Terminated - Down Syndrome Clinical Trials

Storybook Reading in Individuals With Down Syndrome

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

This study uses mobile eye-tracking technology in order to characterize patterns of visual attention to communication supports, as well as a partner, within real world interactions for individuals with Down syndrome. Visual communication supports are central components of what is termed augmentative and alternative communication (AAC) intervention. AAC refers to the methods and technology designed to supplement spoken communication for people with limited speech. "Aided" AAC is a subcategory in which an external aid stores and presents for use visual symbols such as photographs, line drawings, or alphabet letters. The most traditional means of structuring aided AAC displays is to present the language concepts within row-column grids, which contain individual symbols/concepts placed in each grid square. The investigator's previous work investigated whether these grid-based presentations could be improved by understanding how different perceptual features of the displays influence responding (i.e., whether what the display looks like influences how easily the information on it is found). Individuals with developmental disabilities and children developing typically were faster and more accurate in finding information on some displays over others, when tested using a "visual search" task (aka, a "finding game" - "find the dog"). The previous investigations have evaluated visual attention within a setting that isolated visual processing of the AAC display as the primary dependent measure. However, communication requires attention not only to an AAC display, but also to a communication partner. Therefore, the current study seeks to examine questions of visual attention to both an AAC display and a communication partner. The investigators will manipulate characteristics of the structure of the display (e.g., arrangement of symbols), in order to determine if more optimal displays facilitate desirable patterns of visual attention to both the communication display and the partner. The mobile eye-tracking technology captures attention to both the display and the communication partner. The investigators anticipate that participants will be able to attend to their partner and the shared activity more when the AAC display is more optimal, but that when the AAC display is sub-optimal, the participants will have to spend more time examining the AAC display and less time in actual communication.

NCT ID: NCT03763175 Terminated - Clinical trials for Irritable Bowel Syndrome With Constipation

Efficacy and Safety of SYN-010 in IBS-C

Start date: December 24, 2018
Phase: Phase 2
Study type: Interventional

Irritable bowel syndrome (IBS) is a gastrointestinal (GI) syndrome characterized by chronic abdominal pain and altered bowel habits in the absence of any organic cause. The symptoms of IBS not only adversely affect a patient's health-related quality of life (QoL), but also place a significant financial burden on society due to reduced work productivity and increased use of healthcare-related resources. Patients with IBS frequently complain of abdominal bloating and increased gas production in the form of flatulence or belching. The prevalence in North America and Europe is approximately 10-15%. Irritable bowel syndrome affects all ages and genders however there is a 2:1 female predominance in North America. Irritable bowel syndrome is classified into 4 subtypes based on stool pattern: IBS with constipation (IBS-C), IBS with diarrhea, mixed IBS, and un-subtyped IBS. Irritable bowel syndrome with constipation is defined as the presence of hard or lumpy stools with ≥ 25 percent of bowel movements and loose or watery stools with < 25% of bowel movements. SYN-010 is a modified release, oral formulation of lovastatin being developed for the treatment of IBS-C. The SYN-010 program is based predominantly on research by Dr. Mark Pimentel and collaborators hypothesizing that reduction in intestinal methane (methane) production can reverse constipation and improve global symptoms in IBS-C. Methane production in humans is due to methanogenic archaea in the intestine, predominantly Methanobrevibacter smithii (M. smithii). Methane, the key product of anaerobic respiration of methanogens, had been perceived to produce no ill effects in humans aside from gaseous distention. However, several research groups worldwide have shown that a significant percentage of patients with IBS-C excrete methane, and elevated methane production by methanogens correlates with constipation and related symptoms in both IBS-C and chronic idiopathic constipation. A direct causative role for methane in IBS-C was demonstrated in a recent case report, wherein a woman undergoing fecal microbiota transplantation (FMT) for C. difficile infection unknowingly received stool containing a high concentration of methanogens. The FMT recipient rapidly developed severe symptoms of IBS-C that were subsequently reversed by ablation of methane production.

NCT ID: NCT03762317 Terminated - Clinical trials for Neonatal Abstinence Syndrome

Clonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome

Start date: April 30, 2018
Phase: Phase 4
Study type: Interventional

This is a prospective randomized double blinded study comparing the effect on duration of pharmacologic treatment and duration of hospital stay when using clonidine at 12 µg/kilogram/day as an adjunct to oral morphine as compared to morphine monotherapy in the management of term and near term infants with neonatal abstinence syndrome (NAS)

NCT ID: NCT03757416 Terminated - Clinical trials for Carpal Tunnel Syndrome

Flexor Tenosynovectomy to Treat Recurrent Carpal Tunnel Syndrome

Start date: February 2016
Phase:
Study type: Observational

The purpose of this study is to collect data on the clinical and functional outcomes of surgical management for recurrent carpal tunnel syndrome (CTS) using flexor tenosynovectomy. It is hypothesized that the outcomes of patients undergoing flexor tenosynovectomy for recurrent CTS will compare favorably to published data regarding alternative types of surgeries for the same condition.

NCT ID: NCT03735446 Terminated - Clinical trials for Acute Myeloid Leukemia

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Start date: January 18, 2019
Phase: Phase 1
Study type: Interventional

This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). The drugs involved in this study are: - Prexasertib (LY2606368) - Mitoxantrone - Etoposide - Cytarabine

NCT ID: NCT03735316 Terminated - Vasoplegic Syndrome Clinical Trials

Vitamin B12a Vasoplegic Syndrome

Start date: April 25, 2019
Phase: Phase 2
Study type: Interventional

The study team will evaluate the medication Hydroxocobalamin (B12a) for treatment of low blood pressure after cardiac surgery.

NCT ID: NCT03732534 Terminated - Tourette Syndrome Clinical Trials

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Start date: October 17, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 for the treatment of TS for pediatric participants who have taken part in a Phase 2 NBI-98854 study.